A

Open-label
safety/PK component (4 weeks)

Patients* receiving
stable background
MTX (n = 16)

Randomization (1:1)

Maraviroc 300 mg BID + MTX (n = 8)

Maraviroc 150 mg BID + MTX (n = 8)

B

Double-blinded
proof-of-concept component (12 weeks)

Patients receiving
stable background
MTX (n = 110)

Randomization (2:1)

Maraviroc 300 mg BID + MTX (n = 77)

Placebo + MTX (n = 33)

*Patients without any disease activity requirements.
BID = twice daily; MTX = methotrexate; PK = pharmacokinetics.